<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19910">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01782911</url>
  </required_header>
  <id_info>
    <org_study_id>MAD-IO-01-2013-01</org_study_id>
    <nct_id>NCT01782911</nct_id>
  </id_info>
  <brief_title>Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients</brief_title>
  <acronym>RES-IVF</acronym>
  <official_title>Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Undergoing IVF Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, Spain</source>
  <oversight_info>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is characterized by enlarged ovaries, menstrual
      irregularity and hyperandrogenism and is the most common cause of oligoovulatory
      infertility. Insulin resistance with resulting hyperinsulinemia is also common among women
      with PCOS, along with increased risk for dyslipidemia, hypertension, diabetes and related
      cardiovascular consequences. Resveratrol is a natural polyphenol with anti-carcinogenic,
      anti-proliferative and pro-apoptotic properties, that has been shown to decrease
      proliferation and steroidogenesis in theca cells, emerging as a potential therapeutic agent
      in PCOS patients. However, little is known about its potential beneficial effect on oocyte
      quality as well as other reproductive outcomes, such as implantation an pregnancy rates. The
      present study evaluates effects of resveratrol on selected biochemical parameters and
      reproductive outcome among patients with PCOS who undergo in vitro fertilization (IVF).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Effect of resveratrol on oocyte quality</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of resveratrol on testosterone levels.</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of resveratrol on inflammatory markers</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of resveratrol on the fertilization rate.</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of resveratrol on the pregnancy rate.</measure>
    <time_frame>40 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Androgen Profile</condition>
  <condition>Inflammatory Markers</condition>
  <condition>IVF Outcome</condition>
  <arm_group>
    <arm_group_label>Resveratrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>The patients will take 2 g of resveratrol per day for 40 days.</description>
    <arm_group_label>Resveratrol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo pills</intervention_name>
    <description>The patients will take placebo for 40 days.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged from 18 to 40 years old.

          -  PCOS diagnosis (according to Rotterdam criteria).

          -  Mild or moderate male factor, tubal factor or unknown infertility.

        Exclusion Criteria:

          -  Follicle stimulation hormone (third of day of menstruation) &gt; 10 milli international
             units/L.

          -  Endometriosis (III o IV).

          -  Congenital adrenal hyperplasia.

          -  Cushing syndrome.

          -  Hyperprolactinemia.

          -  Thyroid disease.

          -  Androgenic hormone secretor tumors.

          -  Patients included in this trial did not take either oral contraceptives, steroids or
             other medications that could modify the ovarian function, insulin sensitivity or
             lipid metabolism 3 months before the onset of the trial.

          -  Severe male factor (sperm concentration &lt; 5 mill/ml).

          -  Patients undergoing oocyte vitrification to avoid hyperstimulation syndrome will be
             excluded.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Israel Ortega, Medical doctor</last_name>
    <phone>91 180 2900</phone>
    <email>israel.ortega@ivi.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ivi Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>IVI MADRID</last_name>
      <phone>91 180 29 00</phone>
      <email>israel.ortega@ivi.es</email>
    </contact>
    <investigator>
      <last_name>Israel Ortega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 31, 2013</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, Spain</investigator_affiliation>
    <investigator_full_name>Israel Ortega</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Androgen</keyword>
  <keyword>IVF</keyword>
  <keyword>Resveratrol</keyword>
  <keyword>PCOS.</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
